Cancer
Conditions
Keywords
bevacizumab, cancer
Brief summary
Bevacizumab might influence the dynamic vessel function after being administered intravenously.
Detailed description
By monitoring different vessel and circulation parameters (e.g. dynamic retinal vessel analyzer) the study will clarify the potential hemodynamic effects of bevacizumab.
Interventions
single infusion 10 mg/kg
Sponsors
Technische Universität Dresden
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients who wish and need bevacizumab treatment for underlying disease
Exclusion criteria
* previous bevacizumab treatment * known eye disease, eye surgery or eye trauma in history * myopia \>-2.0 dpt * hyperopia \> +2.0 dpt. * relevant media opacity of the lens * acute heart disease, ischemic insult, proven coronary heart disease * cardiac arrhythmia or vessel anomalies * seizure disorder or episode in history * migraine * treatment with corticosteroids within 4 weeks before study inclusion * intake of vasoactive drugs like AT-1 or glitazone * pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diameter of retinal vessels and dynamic vessel reaction | Measurements before and after administration |
Secondary
| Measure | Time frame |
|---|---|
| Baroreflex sensitivity, heart frequence variability, reaction to handgrip test | Measurements before and after administration |
Countries
Germany
Outcome results
None listed